Katina Dorton

Katina Dorton brings to the Board more than 30 years of experience in finance and healthcare, spanning fundraising, mergers and acquisitions, and business development. Ms. Dorton most recently served as Chief Financial Officer of NodThera, a private biotechnology company, from 2020 to 2022. Prior to that, she held CFO roles at Repare Therapeutics from 2019 to 2020, AVROBIO from 2017 to 2019, and Inmatics from 2015 to 2017. Earlier in her career, she worked as a healthcare investment banker at Morgan Stanley and Needham, and practiced M&A and securities law at Sullivan and Cromwell. 

Ms. Dorton currently serves as a director on the boards of Fulcrum Therapeutics, TScan Therapeutics, Sonoma Bio, and Prelude Therapeutics, which she joined in 2020, 2021, 2024, and 2025, respectively. Previous board service includes Pandion Therapeutics from 2020 to 2021, until its acquisition by Merck, and US Ecology from 2015 to 2022, until its acquisition by Republic Services.

She holds a Bachelor of Arts from Duke University, an MBA from George Washington University, and a Juris Doctor from the University of Virginia. She is also NACD Directorship Certified®.